288 related articles for article (PubMed ID: 18827607)
41. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
Ray P; Quantin X; Grenìer J; Pujol JL
Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
[TBL] [Abstract][Full Text] [Related]
42. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
43. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
44. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.
Pujol JL; Molinier O; Ebert W; Daurès JP; Barlesi F; Buccheri G; Paesmans M; Quoix E; Moro-Sibilot D; Szturmowicz M; Bréchot JM; Muley T; Grenier J
Br J Cancer; 2004 Jun; 90(11):2097-105. PubMed ID: 15150567
[TBL] [Abstract][Full Text] [Related]
45. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer.
Shimanuki Y; Takahashi K; Cui R; Hori S; Takahashi F; Miyamoto H; Fukurchi Y
Lung; 2005; 183(1):29-42. PubMed ID: 15793665
[TBL] [Abstract][Full Text] [Related]
46. Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer.
Mroczko B; Szmitkowski M; Niklinski J
Clin Chem Lab Med; 2001 May; 39(5):374-9. PubMed ID: 11434384
[TBL] [Abstract][Full Text] [Related]
47. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
Muley T; Ebert W; Stieber P; Raith H; Holdenrieder S; Nagel D; Fürst H; Roth HJ; Luthe H; Blijenberg BG; Gurr E; Uhl W; von Pawel J; Drings P
Clin Chem Lab Med; 2003 Jan; 41(1):95-103. PubMed ID: 12636057
[TBL] [Abstract][Full Text] [Related]
48. Survival predictors in advanced non-small cell lung cancer.
Hespanhol V; Queiroga H; Magalhães A; Santos AR; Coelho M; Marques A
Lung Cancer; 1995 Dec; 13(3):253-67. PubMed ID: 8719065
[TBL] [Abstract][Full Text] [Related]
49. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
50. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients.
Kaya A; Ciledag A; Gulbay BE; Poyraz BM; Celik G; Sen E; Savas H; Savas I
Respir Med; 2004 Jul; 98(7):632-6. PubMed ID: 15250229
[TBL] [Abstract][Full Text] [Related]
51. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer.
Tamura M; Oda M; Tsunezuka Y; Matsumoto I; Kawakami K; Ohta Y; Watanabe G
Chest; 2004 Aug; 126(2):342-6. PubMed ID: 15302715
[TBL] [Abstract][Full Text] [Related]
52. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer.
Borgia JA; Basu S; Faber LP; Kim AW; Coon JS; Kaiser-Walters KA; Fhied C; Thomas S; Rouhi O; Warren WH; Bonomi P; Liptay MJ
J Thorac Oncol; 2009 Mar; 4(3):338-47. PubMed ID: 19190517
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.
Ono A; Takahashi T; Mori K; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Nakajima T; Endo M; Yamamoto N
BMC Cancer; 2013 Jul; 13():354. PubMed ID: 23879483
[TBL] [Abstract][Full Text] [Related]
54. The relationship between serum VEGF concentration and prognosis of lung cancer.
Park SH; Lee SS
Korean J Intern Med; 2003 Dec; 18(4):207-11. PubMed ID: 14717227
[TBL] [Abstract][Full Text] [Related]
55. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors.
Paone G; De Angelis G; Portalone L; Greco S; Giosué S; Taglienti A; Bisetti A; Ameglio F
Br J Cancer; 1997; 75(3):448-50. PubMed ID: 9020496
[TBL] [Abstract][Full Text] [Related]
56. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
Blankenburg F; Hatz R; Nagel D; Ankerst D; Reinmiedl J; Gruber C; Seidel D; Stieber P
Tumour Biol; 2008; 29(4):272-7. PubMed ID: 18781099
[TBL] [Abstract][Full Text] [Related]
57. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
58. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Massaron S; Cataldo I; Oldani S; Iurlo A; Caldiera S; Bombardieri E
Int J Biol Markers; 1999; 14(2):92-8. PubMed ID: 10399628
[TBL] [Abstract][Full Text] [Related]
59. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions].
Yang JG; Li CL; Gong M; Zou LF
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375
[TBL] [Abstract][Full Text] [Related]
60. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
